Neena Brizmohun
Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Neena Brizmohun
Dual Approval For Verzenio Under International Review Scheme
The joint review by Australia and Canada of the metastatic breast cancer drug, Verzenio, helped regulators in both jurisdictions achieve efficiencies.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Doubts Over Impartiality Trigger New EMA Estradiol Cream Safety Review
A 14-year-old legal dispute has resulted in the European Medicines Agency having again to review and issue recommendations on minimizing the risks associated with high-strength estradiol-containing creams.
New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances now includes two new products, one of which is the injectable migraine prevention drug, Ajovy (fremanezumab). The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
Blow For Novartis As England’s NICE Says No To Kisqali
Novartis is having a harder time than Eli Lilly at getting health technology assessment body NICE to agree to make its breast cancer CDK4/6 inhibitor in combination with fulvestrant available on the National Health Service.
Myeloma CAR T-Therapy Among New EMA PRIME Winners
Janssen, Krystal Biotech and Takeda are the latest companies to win a place on the European Medicines Agency’s popular priority medicines scheme for getting drugs for unmet medical needs through the review process faster.